Nintedanib is an oral, small-molecule tyrosine kinase inhibitor (TKI) developed for the treatment of various fibrotic and oncologic conditions. This drug, which is marketed under the brand names Ofev and Vargatef, has drawn attention from all over the world due to its distinct mode of action and ability to slow the progression of specific types of non-small cell lung cancer (NSCLC), systemic sclerosis-associated interstitial lung disease (SSc-ILD), idiopathic pulmonary fibrosis (IPF), and other chronic fibrosing interstitial lung diseases (ILDs) that exhibit a progressive phenotype.

Mechanism of Action

Numerous receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs) implicated in tumor angiogenesis and fibrogenesis are inhibited by nintedanib. Specifically, it targets the vascular endothelial growth factor receptors (VEGFR 1-3), platelet-derived growth factor receptors (PDGFR α and β), and fibroblast growth factor receptors (FGFR 1-3). Nintedanib decreases fibroblast activity, vascular remodeling, and aberrant tissue scarring—all of which are important factors in the development of tumors and fibrotic diseases—by inhibiting these signaling pathways.

Brand Names and Indications

Ofev is mainly recommended for A chronic, progressive fibrotic lung illness with an unclear etiology, idiopathic pulmonary fibrosis (IPF) is defined by deteriorating lung function. Ofev has been shown to delay the decline in forced vital capacity (FVC), a critical marker of the disease’s progression.

Interstitial lung disease linked to systemic sclerosis (SSc-ILD): Ofev helps people with systemic sclerosis (scleroderma) maintain lung function and reduce lung fibrosis.

Chronic Fibrosing ILDs with a Progressive Phenotype: Ofev reduces the decline of lung function in patients with a variety of interstitial lung diseases that exhibit progressive fibrotic behavior despite treatment.

The main uses of Vargatef are in oncology, particularly for:

Vargatef is used as a second-line treatment for non-small cell lung cancer (NSCLC) in individuals with locally progressed, metastatic, or recurrent NSCLC of adenocarcinoma histology following first-line chemotherapy when combined with docetaxel.

Pharmacokinetics

Nintedanib (Ofev and Vargatef) is usually taken orally twice a day. It goes through a lot of first-pass metabolism, which includes glucuronidation after ester hydrolysis. Peak plasma concentrations are attained two to four hours after injection, and its bioavailability is roughly 5%. Nintedanib has little renal clearance and is mostly removed by fecal excretion.

Side Effects and Safety

Nintedanib, like the majority of TKIs, has several adverse effects, the most prevalent of which are:

Effects on the stomach: The most commonly reported adverse effect is diarrhea, which may call for dose modifications or antidiarrheal medication.

Elevations of liver enzymes: It is advised to regularly check liver function tests.

Discomfort, nausea, and vomiting

Loss of weight and appetite

Bleeding risk: Nintedanib’s anti-angiogenic properties may make bleeding more likely, particularly in individuals using anticoagulants.

Although it works well, nintedanib does not cure the illnesses it addresses. Its main goal is to delay functional decline and improve quality of life by slowing the progression of the disease.

Contraindications and Precautions

Patients who have a history of known hypersensitivity to nintedanib or its excipients should not take it. Patients with cardiovascular illness, hepatic impairment, a history of thromboembolic events, or a gastrointestinal perforation should exercise caution. It is not recommended during pregnancy due to potential dangers to the fetus.

Conclusion

Nintedanib (Ofev and Vargatef), sold under the brand names Ofev and Vargatef, is a significant advancement in the management of fibrotic lung diseases and many forms of cancer. It aids in the treatment of progressive diseases for which there were previously few effective treatments by focusing on important growth factor receptors implicated in fibrosis and angiogenesis. Nintedanib is still a mainstay of contemporary treatment plans for IPF, SSc-ILD, and NSCLC, despite a few tolerable side effects.

Order Now At Mdx Pharma bd….

To order from MDX Pharma BD, visit their website at https://mdxpharmabd.com, where you can browse products and place orders online. For inquiries or orders via email, contact emedicarepharma@gmail.com. Alternatively, call (+88) 01929123476. Their address is 29, Abdullahpur, Uttara, Dhaka-1230, Bangladesh.

1. What is the purpose of nintedanib?
Nintedanib is utilized to treat:
IPF, or idiopathic pulmonary fibrosis
Interstitial lung disease linked to systemic sclerosis (SSc-ILD)
Progressive phenotype of chronic fibrosing interstitial lung disorders
It is also used as Vargatef in combination with chemotherapy for non-small cell lung cancer (NSCLC) of the adenocarcinoma type.

2. Nintedanib: How does it work?
Tyrosine kinase inhibitors include nintedanib. It inhibits several growth factor receptors that are implicated in angiogenesis and fibrosis, including FGFR, VEGFR, and PDGFR. This lowers the tumor blood supply in cancer and inhibits the progression of lung fibrosis.

3. How does one take Nintedanib?
To minimize gastrointestinal side effects, it is often taken orally in doses of 150 mg twice a day, spaced about 12 hours apart, and with meals.

4. What kind of monitoring is required when using Nintedanib?
Tests of liver function (LFTs) both before and during therapy
monitoring of blood pressure
keeping an eye out for bleeding and GI symptoms
Complete blood count, or CBC, is utilized in cancer treatment.

5. Is it safe to use Nintedanib when pregnant?
The answer is no. Because of the possibility of fetal damage, nintedanib should not be used during pregnancy. Effective contraception should be used by women who are capable of bearing children.